Noxopharm Secures Ethics Approval for First-in-Human Trial of Inflammatory Disease Drug Candidate; Shares Up 6%

MT Newswires Live
05-29

Noxopharm (ASX:NOX) secured Human Research Ethics Committee approval for the Heracles clinical trial, a first-in-human trial for SOF-SKN, a novel drug candidate for chronic inflammatory diseases, according to a Thursday filing with the Australian bourse.

The trial will assess SOF-SKN's safety profile at four concentrations, working with Doherty Clinical Trials in Melbourne to advance operational aspects like site initiation, batch preparation, and participant screening and recruitment, the filing said.

Shares rose 6% in afternoon trade Thursday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10